Enzychem Lifesciences Corporation (183490.KQ) stock: key figures, P/E, revenue and dividend
Health Care · South Korea
Enzychem Lifesciences Corporation financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 77.38 bn KRW | 67.75 bn KRW |
| Gross profit | 4.31 bn KRW | 3.38 bn KRW |
| Operating income | -19.94 bn KRW | -13.09 bn KRW |
| EBIT | -21.85 bn KRW | -18.04 bn KRW |
| Net income | -22.11 bn KRW | -18.13 bn KRW |
| Diluted EPS – continuing operations | -277.65 KRW | -242.18 KRW |
Full history since 2022, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Enzychem Lifesciences Corporation
Enzychem Lifesciences Corporation engages in developing novel small molecule therapeutics for patients with unmet needs for oncology, inflammatory, and severe respiratory diseases in South Korea. It is also developing EC-18, an oral small molecule for fibrotic diseases, such as nonalcoholic steatohepatitis; and in severe respiratory diseases as a potential therapy for COVID-19. The company was founded in 1999 and is headquartered in Seoul, South Korea.
More stocks
- FST Corp. Ordinary Shares (KBSX)
- Taewoong Logistics Co.Ltd (124560.KQ)
- Yenher Holdings Bhd (5300.KL)
- Global View Co Ltd (3040.TW)
- AMS Advanced Material Berhad (0399.KL)
- Hong Ho Precision Textile Co Ltd (1446.TW)
- Aurea SA (AURE.PA)
- Sum Technology Berhad (0459.KL)
- Infinity Bank (Santa Ana CA) (INFT)
- PRECISION OPTICS CORPORATION, INC. (POCI)
- Rock Tech Lithium Inc (RCK.V)
- Noble Development Public Company Limited (NOBLE.BK)
Not investment advice. All data without warranty, price as of 23.03.2026. Details in the risk notice.